University of Chicago Medicine Comprehensive Cancer Center | Strategic Alliance Partners

March 05, 2020

Michael R. Charlton, MD, MBBS, discusses the emergence of biomarkers in hepatocellular carcinoma.

February 06, 2020

Rita Nanda, MD, discusses ongoing advances with immunotherapy in triple-negative breast cancer, as well as develops in the HER2-negative breast cancer paradigm.

December 07, 2019

Daniel Catenacci, MD, discusses factors that may guide treatment selection for patients with esophagogastric junction adenocarcinoma.

November 27, 2019

Jyoti D. Patel, MD, discusses the results of the CheckMate-227 trial, which looked at an immunotherapy combination versus chemotherapy in patients with advanced non–small cell lung cancer.

November 22, 2019

Jyoti D. Patel, MD, discusses immunotherapy combinations for patients with advanced nonsquamous non–small cell lung cancer.

November 22, 2019

Everett E. Vokes, MD, discusses remaining questions in stage III non–small cell lung cancer following the PACIFIC results.

November 21, 2019

Jeremy Segal, MD, PhD, discusses pathologic considerations in non–small cell lung cancer and the evolving role of molecular testing.

November 21, 2019

Everett E. Vokes, MD, discusses unanswered questions from the phase III PACIFIC trial in stage III non–small cell lung cancer.

November 18, 2019

Jyoti D. Patel, MD, FASCO, discusses the implications of genetic testing, the lasting impact of the KEYNOTE and IMpower trials in patients with advanced nonsquamous non–small cell lung cancer, and considerations for treatment selection.

November 15, 2019

Christine Bestvina, MD, discusses the phase III KEYNOTE-407 trial in squamous non–small cell lung cancer.

October 29, 2019

Jyoti D. Patel, MD, discusses current immunotherapy options in stage IV non–small cell lung cancer.

August 01, 2019

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, dean for clinical research, director of the Genitourinary Oncology Program, and deputy director of the Comprehensive Cancer Center, at the University of Chicago Medicine, discusses the use of active surveillance in prostate cancer.

April 11, 2019

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses the therapeutic landscape of renal cell carcinoma (RCC).

February 14, 2019

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the management of TKI-associated adverse events in kidney cancer.

February 14, 2019

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses challenges with PD-L1 testing in patients with bladder cancer.

January 24, 2019

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the standard of care in patients with non-muscle invasive bladder cancer (NMIBC).

January 17, 2019

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses the importance of identifying molecular subsets in urothelial cancer.

November 08, 2018

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses ongoing immunotherapy trials in bladder cancer.

November 02, 2018

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses PD-L1 testing in patients with bladder cancer.

October 25, 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses immunotherapy combinations in kidney cancer.